We describe a procedure for determining clorazepate dipotassium as its decarboxylated, pharmacologically active metabolite, desmethyldiazepam, in 100 4 of plasma, with use of electron-capture gas-liquid chromatography and with methylnitrazepam as the internal standard. The procedure is a one-tube, one-step extraction without derivative formation and is accurate, reproducible, and rapid. The sensitivity limit is 20 tg/L. Within-run and between-run CV's (concentration, 3.5 mg/L) were 2.9 and 3.5%, respectively. Within-run Cv's for 1.5 and 1.0 mg/L concentrations were 3.9 and 4.3%, respectively. For a 1.0 mg/kg per day dose of clorazepate dipotassium, the mean steady-state concentration of desmethyldiazepam in plasma was 1.037 mg/L.
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AddItIonalKeyphrases: monitoring therapy epilepsy anti-anxiety therapy
Chlorazepate dipotassium (Tranxene, Abbott) is used for the symptomatic relief of anxiety associated with anxiety neurosis, in other psychoneuroses in which anxiety symptoms are prominent features, as an adjunct in disease states in which anxiety is manifested, and for symptomatic relief of acute alcohol withdrawal. For these purposes the recommended daily dose is from 15 to 60 mg. Recently, it has also been used for treatment of certain types of epilepsy, in which case the dosage can approach 300mg (1). Monitoring therapeutic concentrations of anticonvulsants in the blood is of great importance in the clinical management of epilepsy (2) .
Clorazepate dipotassium (7-chloro-1-3,-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid, monopotassium salt, monopotassium hydroxide) (I) spontaneously decarboxylates to desmethyldiazepam (7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-one) (II) at below pH 4, but is relatively stable at pH 7.4 and above (3) . Thus, in the acidic environment of the stomach, I becomes II, which is also the active metabolite of diazepam III (Valium, Roche) ( Figure  1 ).
Desmethyldiazepam can be measured by gas-liquid chromatography (GLC) with electron-capture (EC) detector (4, 5) and by nitrogen-sensitive detector (6) .
We describe here a simple procedure (applicable to routine use) for analyzing desmethyldiazepam by use of a linear EC-GLC instrument and a highly convenient one-step extracting method originally developed by Weinfeld et al. (7) for determination of diazepam and desmethyldiazepam in patients being treated with diazepam. Emphasis here is on the determination of steady-state concentration of desmethyldiazepam in plasma after administration of relatively high doses of clorazepate dipotassium to patients for seizure control. We made no attempt to estimate intact clorazepate dipotassium, because 4 to 12 h after a dose no clorazepate can be detected (3) .
Materials and Methods

Gas Chromatography
We used a Hewlett-Packard gas-chromatograph, Model College, PA 16801) was used. The column was conditioned at 325 #{176}C for 4 h at "no flow" state and then at 275 #{176}C overnight with argon-methane (90/10 by vol) at 40 mL/min. Analysis conditions: Oven temp., 240 #{176}C; injection port temp. 300 #{176}C,
and EC detector at 400 #{176}C. The flow rate was adjusted so as to obtain retention times of about 4.0 and 6.0 mm for desmethyldiazepam and methylnitrazepam (the internal standard), respectively. At the beginning of each working day, the column was primed by injecting five drug-free blank plasma extracts or previously used calibrator plasma extracts, to avoid peak-tailing for desmethyldiazepam.
Reagents
All solvents were psticide grade or "Glass Distilled"
(Burdick & Jackson, Muskegon, MI 49442). Saturated potassium chloride (reagent grade), approx. 4.8 mol/L, was prepared in distilled water. Analytically pure desmethyldiazepam and methylnitrazepam were generous gifts from Hoffmann-La Roche, Nutley, NJ 07110. The drugs were used as received, after drying in a desiccator at reduced pressure.
Standard Solutions
Place 10.00 mg of desmethyldiazepam in a 10-mL volumetric flask, dissolve it in 1.0 mL of absolute ethanol, and dilute to volume with benzene, to yield a stock solution (1.0 gIL). Prepare a working solution, 10 mg/L, by diluting 1.0 mL of this stock solution 100-fold with benzene. Place 10 to 50 iL (100 to 500 ng) into a series of tubes and evaporate the solvent in a gentle stream of nitrogen. Add 0.1 mL of drug-free blank plasma, vortex mix. These standards are now ready to be run along with patients' specimens for extraction. Place 10 mg of methylnitrazepam (internal standard) in a 100-mL volumetric flask, dissolve it in 10 mL of absolute ethanol, and dilute to volume with benzene to yield a 100 mgIL stock solution. From this, prepare a 10 mg/L solution, and dilute a 250-tL portion of this to 100 mL with benzene to give a 25 zgfL solution.
Methods
Into 13 X 100 mm test tubes (Corning 9810) with ungreased pennyhead stoppers place 0.1 mL of plasma and 0.1 mL of saturated potassium chloride solution (for specimens containing trace quantities of desmethyldiazepam, up to 1.0 mL of plasma and an equal volume of saturated KCI can be used Along with the patients' plasma prepare tubes for a working standard curve for 0 to 500 ng/0.1 mL of plasma. Inject 10 izL of each extract into the gas chromatograph. Chromatograph extracts the same day they are made.
Results
Peak identification:
When 10 LL of each of the aboveprepared calibration specimens was injected (1, 2, 3,4, and 5 ng on the column), the response was linear to concentration. The recovery efficiency of desmethyldiazepam and methylnitrazepam at physiological pH has already been studied in detail (7) . Under research conditions, we were able to confirm the near-100% recovery. Nevertheless, under routine clinical laboratory conditions, recovery varied, and at times was as low as 77%. We believe this variation is attributable to difficulty in maintaining strictly constant and optimal conditions in routine operation. Therefore, each working day the patients' results were based on recalibration of freshly extracted standards included in each run. a All patientsalso had therapeutic plasma concentrations of phenytoin, carbamazeplne, and/orvalproicacid. dure to be within acceptable range of precision and accuracy. At 350 ng/0.1 mL, the assay value was 352.5 ± 12.3 (SD) with a CV of 3.5%; at 150 ngIO. 1 mL it was 164.8 ± 6.5 (SD) with a CV of 3.9%; at 100 ng/0.1 mL it was 110.5 ± 4.7 (SD) with a CV of 4.3%.
Discussion
We have used this procedure for six months and finditto be accurate, reproducible, and rapid. We included specimens supplemented with desmethyldiazepam at every two patients' sample intervals, in duplicate, with duplicate injections of each extract. Our results led us to institute this method for routine clinical laboratory use at Lafayette Clinic. what might be an oxazepam peak in some of our patients' plasma. What appears to be a poor extraction efficiency under our conditions coupled with our routine use of only0.1 mL of plasma for extraction prevents our reporting anything definitive on the relation (if any) between the concentration of desmethyldiazepam in plasma and the presence of oxazepam. Table 1 shows typical steady-state desmethyldiazepam concentrations for some patients on a relatively high dosage of clorazepate dipotassium. Based on these initial data, for 1.0 mglkg daily dose of clorazepate dipotassium, the mean (n = 8) steady-state concentration of desmethyldiazepam is 1.037 mgfL of plasma.
